Something new in the treatment arsenal?

So much good information from patient experience to clinical trial results. It does sound very promising. Thanks to everyone for sharing your story and expertise.

Here is the link to the latest results on this trial.
https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html

Thank you @leeann66 for that great summary of your treatment experience. It’s all helpful to know. You’ve been through a lot but I’m glad you feel like you have good quality of life right now and can still participate in the activities you love with the proper rest in between. You’re a trooper with a great attitude. This new treatment sounds very promising for everyone. Prayers for your continued improvement. Zebra

Hello,

I was diagnosed stage 4 June 2020 with mets to my bones, started on Kisqali and Anastrozole July 13. After 19 months I started to get pain in my breast, similar to when I was diagnosed. I told my oncologist that I thought the cancer was growing again and a scan showed that it was. I switched to Afinitor and Exemastane but had a bad rash and trouble breathing so was taken off after 6 weeks. I was then on Xeloda for 6 months, I didn't have any indication from my body on how it was doing but scans at 3 months then at 6 months showed it wasn't working and the cancer had progressed.

I was without treatment for 7 weeks while my oncologist tried to get me into this trial, and I started in the Tropion 01 trial November 1. Adjusting to side effects was a bit of a journey but now with the right combination of medication for constipation and nausea (which only happened day 4 and 5 post chemo which is every 3 weeks) things are very manageable.

I have no hair anywhere and have fatigue, but I do all the things I need to do around the house, I go to dragon boat practice twice a week, golf once a week, dinners and drinks with my hubby and our friends and weekends are busy with our 4 kids and 2 grandkids. I am not missing out on anything. Yes, I have to rest more and there have been challenges with chemo mouth sores but again, getting the right combination of medications for all side effects is giving me a very good quality of life!!!

Let me know if you have any other questions, happy to share.

Hi @leeann66 That's great that you're in the Phase 3 trial and experiencing such good results! Sorry to hear you had all those qualifications, but I'd love to hear more about your experience on Tropion as well. What are the side-effects and how does your quality of life compare to when you were on each of the other meds?

I've been on Kisqali for 2 yrs 8 mo. Can you tell me how long Kisqali was effective for you? What about Afinitor and Xeloda? How long were those effective? Could you tell the meds were no longer working or was the determination solely based on scan results? Thanks for any info.

Great question! I am in the same position. Would love more information thank you. Maria

This is a very good news. How about side effects, quality of life? Is it manageable?

Hello, I am in Montreal and I am in Phase 3 of the trial you are talking about.

The trial is called Tropion 01 for HR+ HER2 - (or low). I started Nov 1, 2022.

To qualify you have to be stage 4 and have already tried a few other lines of treatment. I had been on Kisqali, Afinitor, and Xeloda prior to this trial.

When I started the trial, I had a tumour in my left breast, several lymph nodes under my left arm were impacted, and I had Mets in my hips, my lower spine, my sixth rib, one of my vertebrae‘s and my sternum. Currently the only cancer that can be seen on The CT scan is in three of my lymph nodes, which is significantly smaller.

I imagine we will be hearing more talk about this at the San Antonio symposiu

Typo above: should read Verzenio Et al, such as Imbrance and Kisquali.

I think it’s not “mature” enough data … not enough years to evaluate relative to meds in the field for longer. Even Verzenio Ry al’s do not have “ mature” data.

Looking very promising however. I’m sure it will be a huge topic at the San Antonio Breast Cancer Symposium in December.